- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Suven Life Sciences Limited — Updates, 17-06-2026: Press Release
17-06-2026 | 12:35 pm
17-06-2026 | 12:35 pm
Suven Life Sciences announced positive Phase-2b results for Ropanicant (SUVN-911) in Major Depressive Disorder, showing clinically meaningful improvement and good tolerability. A global Phase-3 study is being planned, a key de-risking event for this pipeline asset.
No comments yet. Be the first to comment!